Investor Relations
NKGen strives to bring transformative NK cell therapies to patients with neurodegenerative diseases and cancer.
NKGen strives to bring transformative NK cell therapies to patients with neurodegenerative diseases and cancer.
// Setup event listener
var eventMethod = window.addEventListener ? "addEventListener" : "attachEvent";
var eventer = window[eventMethod];
var messageEvent = eventMethod == "attachEvent" ? "onmessage" : "message";
// Listen for event
eventer(messageEvent, function (e) {
// Check that message being passed is the documentHeight
var height = e.data;
// Set iframe height based on the height received
var ksFrame = document.getElementById('ks-frame');
ksFrame.style.height = height + 'px';
}, false);
NKGen Biotech’s mission is to improve patient outcomes in neurodegenerative disease and cancer by developing safe and effective cellular therapies that leverage the power of a patient’s immune system. NKGen’s vision is to become the global leader in NK cell therapies.
NKGen Biotech is a clinical-stage biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. NKGen’s product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells with increased activity (defined by parameters such as cytotoxicity, cytokine production and activating receptor expression) as compared to the starting NK cell population.
SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. NKGen believes that SNK cells have the potential to deliver transformational benefits to patients with both neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, and cancer.
NKGen Biotech’s industry-leading management team, board of directors and scientific advisors have significant expertise across every aspect of our business. Our scientific advisors, with deep experience in immunology, neurology and oncology, help us advance our clinical trial programs with the goal of bringing life changing NK cell therapies to patients in need.
NKGen Biotech is located in Orange County, California a thriving industry hub for innovative biomedical and life science companies.
NKGen Biotech, Inc.
3001 Daimier Street
Santa Ana, CA 94080
investors@nkgenbiotech.com
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
NKGen Biotech Selected as Stalking Horse Bidder for NKMax